참고문헌
- Yoshida N, Ito T, Karasawa T, Itoh Z. AS-4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs. J Pharmacol Exp Ther. 1991;257:781-787.
- Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs . 2008;68:981-991. https://doi.org/10.2165/00003495-200868070-00007
-
Yoshikawa T, Yoshida N, Mine Y, Hosoki K. Affinity of mosapride citrate, a new gastroprokinetic agent, for
$5-HT_{4}$ receptors in guinea pig ileum. Jpn J Pharmacol. 1998;77:53-59. https://doi.org/10.1254/jjp.77.53 - Wade PR, Mawe GM, Branchek TA, Gershon MD. Use of stereoisomers of zacopride to analyze actions of 5-hydroxytryptamine on enteric neurons. Am J Physiol. 1991;260(1 Pt 1):G80-G90.
- Nemeth PR, Ort CA, Zafirov DH, Wood JD. Interactions between serotonin and cisapride on myenteric neurons. Eur J Pharmacol. 1985;108:77-83. https://doi.org/10.1016/0014-2999(85)90285-7
- Nemeth PR, Gullikson GW. Gastrointestinal motility stimulating drugs and 5-HT receptors on myenteric neurons. Eur J Pharmacol. 1989;166:387-391. https://doi.org/10.1016/0014-2999(89)90350-6
- Wu ZS, Cheng H, Jiang Y, Melcher K, Xu HE. Ion channels gated by acetylcholine and serotonin: structures, biology, and drug discovery. Acta Pharmacol Sin. 2015;36:895-907. https://doi.org/10.1038/aps.2015.66
-
Sugita S, Shen KZ, North RA. 5-hydroxytryptamine is a fast excitatory transmitter at
$5-HT_{3}$ receptors in rat amygdala. Neuron. 1992;8:199-203. https://doi.org/10.1016/0896-6273(92)90121-S - Morales M, Battenberg E, de Lecea L, Sanna PP, Bloom FE. Cellular and subcellular immunolocalization of the type 3 serotonin receptor in the rat central nervous system. Brain Res Mol Brain Res. 1996;36:251-260. https://doi.org/10.1016/0169-328X(96)88406-3
-
Holbrook JD, Gill CH, Zebda N, Spencer JP, Leyland R, Rance KH, Trinh H, Balmer G, Kelly FM, Yusaf SP, Courtenay N, Luck J, Rhodes A, Modha S, Moore SE, Sanger GJ, Gunthorpe MJ. Characterisation of
$5-HT_{3C}$ ,$5-HT_{3D}$ and$5-HT_{3E}$ receptor subunits: evolution, distribution and function. J Neurochem. 2009;108:384-396. https://doi.org/10.1111/j.1471-4159.2008.05775.x - Miyake A, Mochizuki S, Takemoto Y, Akuzawa S. Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol. 1995;48:407-416.
-
Akuzawa S, Miyake A, Miyata K, Fukutomi H. Comparison of
$[^{3}H]$ YM060 binding to native and cloned rat$5-HT_{3}$ receptors. Eur J Pharmacol. 1996;296:227-230. https://doi.org/10.1016/0014-2999(95)00798-9 -
Walstab J, Rappold G, Niesler B.
$5-HT_{3}$ receptors: role in disease and target of drugs. Pharmacol Ther. 2010;128:146-169. https://doi.org/10.1016/j.pharmthera.2010.07.001 -
Thompson AJ. Recent developments in
$5-HT_{3}$ receptor pharmacology. Trends Pharmacol Sci. 2013;34:100-109. https://doi.org/10.1016/j.tips.2012.12.002 -
Fakhfouri G, Rahimian R, Ghia JE, Khan WI, Dehpour AR. Impact of
$5-HT_{3}$ receptor antagonists on peripheral and central diseases. Drug Discov Today. 2012;17:741-747. https://doi.org/10.1016/j.drudis.2012.02.009 -
Machu TK. Therapeutics of
$5-HT_{3}$ receptor antagonists: current uses and future directions. Pharmacol Ther. 2011;130:338-347. https://doi.org/10.1016/j.pharmthera.2011.02.003 - Zheng Y, Yu T, Tang Y, Xiong W, Shen X, Jiang L, Lin L. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0172846. https://doi.org/10.1371/journal.pone.0172846
- Park YS, Myeong SH, Kim IB, Sung KW. Tricyclic antidepressant amitriptyline inhibits 5-hydroxytryptamine 3 receptor currents in NCB-20 cells. Korean J Physiol Pharmacol. 2018;22:585-595. https://doi.org/10.4196/kjpp.2018.22.5.585
- Snyders D, Hondeghem L, Bennett P. Mechanisms of drug-channel interaction. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, editors. The heart and cardiovascular system: scientific foundations, vol. 2. New York: Raven Press; 1992.
-
Zhou Q, Verdoorn TA, Lovinger DM. Alcohols potentiate the function of
$5-HT_{3}$ receptor-channels on NCB-20 neuroblastoma cells by favouring and stabilizing the open channel state. J Physiol. 1998;507(Pt 2):335-352. https://doi.org/10.1111/j.1469-7793.1998.335bt.x -
van Hooft JA, van der Haar E, Vijverberg HP. Allosteric potentiation of the
$5-HT_{3}$ receptor-mediated ion current in N1E-115 neuroblastoma cells by 5-hydroxyindole and analogues. Neuropharmacology. 1997;36:649-653. https://doi.org/10.1016/S0028-3908(97)00045-2 -
Neijt HC, Plomp JJ, Vijverberg HP. Kinetics of the membrane current mediated by serotonin
$5-HT_{3}$ receptors in cultured mouse neuroblastoma cells. J Physiol. 1989;411:257-269. https://doi.org/10.1113/jphysiol.1989.sp017572 -
Gunthorpe MJ, Lummis SC. Diltiazem causes open channel block of recombinant
$5-HT_{3}$ receptors. J Physiol. 1999;519 Pt 3:713-722. https://doi.org/10.1111/j.1469-7793.1999.0713n.x - Nayak SV, Ronde P, Spier AD, Lummis SC, Nichols RA. Calcium changes induced by presynaptic 5-hydroxytryptamine-3 serotonin receptors on isolated terminals from various regions of the rat brain. Neuroscience. 1999;91:107-117. https://doi.org/10.1016/S0306-4522(98)00520-X
-
Thompson AJ, Lummis SC.
$5-HT_{3}$ receptors. Curr Pharm Des. 2006;12:3615-3630. https://doi.org/10.2174/138161206778522029 - Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397-414. https://doi.org/10.1053/j.gastro.2006.11.002
-
Gregory RE, Ettinger DS.
$5-HT_{3}$ receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998;55:173-189. https://doi.org/10.2165/00003495-199855020-00002 - Galligan JJ, LePard KJ, Schneider DA, Zhou X. Multiple mechanisms of fast excitatory synaptic transmission in the enteric nervous system. J Auton Nerv Syst. 2000;81:97-103. https://doi.org/10.1016/S0165-1838(00)00130-2
- Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10:473-486. https://doi.org/10.1038/nrgastro.2013.105
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491. https://doi.org/10.1053/j.gastro.2005.11.061
- Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20:8867-8885. https://doi.org/10.3748/wjg.v20.i27.8867
- Karasawa T, Yoshida N, Furukawa K, Omoya H, Ito T. Comparison of gastrokinetic effects of AS-4370, cisapride and BRL24924. Eur J Pharmacol. 1990;183:2181. https://doi.org/10.1016/0014-2999(90)93708-X